Immatics N.V. Updates IMA203 Trial Data
Ticker: IMTX · Form: 6-K · Filed: Jun 2, 2025 · CIK: 1809196
Sentiment: neutral
Topics: clinical-trial, biotech, oncology
TL;DR
Immatics drops new melanoma cell therapy data from Phase 1b trial.
AI Summary
Immatics N.V. announced on June 2, 2025, updated Phase 1b clinical trial data for its IMA203 PRAME cell therapy. The data, with a cutoff of April 7, 2025, involved 33 heavily pretreated metastatic melanoma patients who received a single infusion of IMA203 at the recommended Phase 2 dose.
Why It Matters
This data provides insights into the efficacy and safety of Immatics' novel cell therapy for a difficult-to-treat cancer, potentially impacting future treatment options for melanoma patients.
Risk Assessment
Risk Level: medium — Clinical trial data updates can be positive or negative, impacting investor sentiment and the company's future prospects.
Key Numbers
- 33 — Patients (Number of heavily pretreated metastatic melanoma patients in the Phase 1b trial.)
Key Players & Entities
- Immatics N.V. (company) — Registrant and developer of IMA203
- IMA203 (drug) — PRAME cell therapy being evaluated
- April 7, 2025 (date) — Data cutoff date for the clinical trial
- June 2, 2025 (date) — Date of the 6-K filing
- 33 (number) — Number of patients in the trial
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K filing provides updated data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy.
What specific therapy is Immatics N.V. evaluating?
Immatics N.V. is evaluating IMA203 PRAME cell therapy.
What type of patients are included in the trial?
The trial includes heavily pretreated patients with metastatic melanoma.
What was the data cutoff date for the reported trial results?
The data cutoff date was April 7, 2025.
At what dose was IMA203 administered to the patients?
IMA203 was administered at the recommended Phase 2 dose (RP2D).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 2, 2025 regarding Immatics N.V. (IMTX).